Form 4: Inovio Pharmaceuticals CFO Peter Kies Reports Stock and Option Awards
SEC Form 4
CFO of Inovio Pharmaceuticals, Peter Kies, reports the acquisition of restricted stock units and stock options.
Summary
- Peter Kies, CFO of Inovio Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On May 20, 2025, Kies acquired 26,100 restricted stock units (RSUs) and 31,950 stock options.
- The RSUs vest in three equal installments of 8,700 shares on May 20, 2026, May 20, 2027, and May 20, 2028.
- The stock options vest in two equal installments of 15,975 shares on May 20, 2027, and May 20, 2028.
- The exercise price for the options is $2.13.
- Following the reported transactions, Kies directly owns 26,100 RSUs and 31,950 stock options.
Sentiment
Score: 6
Explanation: The document is a neutral regulatory filing. The grant of equity can be seen as a positive sign of aligning management interests, but it's a routine event.
Positives
- The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates compensation in the form of equity.
Comparison to Industry Standards
- Equity compensation is a common practice in the biotechnology industry to attract and retain key executives.
- Companies like Moderna (MRNA) and BioNTech (BNTX) also utilize stock options and restricted stock units as part of their executive compensation packages.
- The vesting schedules are typical for such grants, aligning executive incentives with long-term company performance.
Stakeholder Impact
- Shareholders may view the equity grants as aligning management's interests with the company's long-term success.
- Employees may see the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of transaction: Acquisition of restricted stock units and stock options. |
| 05/20/2026 | Vesting date for 8,700 restricted stock units. |
| 05/20/2027 | Vesting date for 8,700 restricted stock units and 15,975 stock options. |
| 05/20/2028 | Vesting date for 8,700 restricted stock units and 15,975 stock options. |
| 05/20/2035 | Expiration date for the stock options. |
| 05/21/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Inovio Pharmaceuticals, Peter Kies, CFO, Restricted Stock Units, Stock Options, Beneficial Ownership, INO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.